SNMMI collaborates with industry leaders to advance molecular imaging
On May 17, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced the Value Initiative Industry Alliance—a collaboration among corporate community members that will help implement the organization’s Value Initiative and advance nuclear medicine.
SNMMI’s Value Initiative is the basis of a new strategic plan, according to a press release from the organization, that focuses on five key areas: Quality of practice, research and development, workforce pipeline, advocacy and outreach. Its goal is to demonstrate the crucial role nuclear medicine and molecular imaging have in delivering quality care.
The Value Alliance members will provide funding support, strategic industry guidance and knowledge-sharing to help shape the future of nuclear medicine, according to the release. It is co-chaired by Jonathan Allis, DPhil, and CEO of Blue Earth Diagnostics and James Williams, PhD, and Head of Siemens Healthineers Molecular Imaging.
“SNMMI is proud to work with these industry leaders and their companies, and honored to strengthen that collaboration through the Value Initiative Industry Alliance,” said SNMMI Vice President Satoshi Minoshima, MD, PhD, who chairs the Value Initiative Board. “Innovative nuclear medicine and molecular imaging research is beginning to transform precision medicine and patient outcomes. Working together with Alliance participants, which range from small businesses to the largest corporations in the industry, we can advance scientific discoveries and rapidly translate them to patient care with more effective diagnostics and targeted therapy.”
Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.